The SARS-CoV-2 USA_WA1/2020 (SARS-CoV-2/human/USA/WA-CDC-02982586-001/2020, GenBank: MN985325.1) and B.1.1.529 (Omicron) sublineage BA.5.5 (hCoV-19/USA/COR-22-063113/2022, GISAID accession ID: EPI_ISL_13512579) were obtained from the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA, University of Texas Medical Branch, Galveston, TX, USA). Both viruses were passaged once in VeroE6-TMPRSS2 cells for subsequent experiments and deep sequenced to verify single nucleotide variants (SNVs) frequencies along the whole genome at the UTMB’s Next Generation Sequencing (NGS) Core, directed by Dr. Steven G. Widen. Deep sequencing of these stocks revealed no mutations or deletions in the Spike protein >5.0% frequency.
VeroE6 cell line expressing human TMPRSS2 were obtained from JCRB Cell Bank (JCRB1819, lot 04172020)36 (link). VeroE6-TMPRSS2 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco/Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum and 100 µg/ml of Geneticin™ Selective Antibiotic - G418 Sulfate (Thermo Fisher Scientific). VeroE6-TMPRSS2 cell line was verified and tested negative for mycoplasma before use.
VeroE6 cell line expressing human TMPRSS2 were obtained from JCRB Cell Bank (JCRB1819, lot 04172020)36 (link). VeroE6-TMPRSS2 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco/Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum and 100 µg/ml of Geneticin™ Selective Antibiotic - G418 Sulfate (Thermo Fisher Scientific). VeroE6-TMPRSS2 cell line was verified and tested negative for mycoplasma before use.
Free full text: Click here
